Fish Leap Medical's 550 million yuan acquisition of 38.38 percent of China Excellent Pharma's shares to achieve full control

"From the acquisition of Suzhou medical supplies in 2009, Fish Leap Medical seems to have discovered the "new continent" in the field of medical supplies, and then through continuous acquisition, the product line gradually became a scale, from the 2017 action, clinical medical business has become a key cultivation sector.
The Group and China Excellent Medicine are the leading big brothers in their respective sub-channels, the channel resources are strong, and strong synergy, to achieve who-owned holding, fish leap medical in the allocation of resources more handy.Realize wholly-owned holding
Yesterday, Fish Leap Medical announced that it had signed a Letter of Intent on the Transfer of Shares of Shanghai Zhongyou Pharmaceutical High-Tech Co., Ltd. on January 23, proposing to acquire 38.3775 percent of the shares of Shanghai Zhongyou Pharmaceutical High-Tech Co., Ltd., which the two sides initially agreed to transfer the underlying company at a price of not more than 550 million yuan, to be paid in cash.
data show that the business of Chinese and excellent medicine includes pharmaceutical, cosmetics technology development, second-class medical equipment, disinfectants, hygiene products sales. It is worth mentioning that the disinfection industry business of Chinese and excellent medicine at home and abroad at different levels of hospitals have a better brand precipitation, especially in the field of hand and skin disinfection, "Jefurou", "Iodine" and other well-known brands in the hospital foundation is solid.
, China Excellent Pharma had two major shareholders, of which Fish Leap Medical held 61.625 million shares, accounting for 61.62 percent, and Yu Xuelian held 38.3775 million shares, accounting for 38.38 percent.
the acquisition, Zhongyou Pharmaceuticals will directly or indirectly become a wholly owned subsidiary of Fish Leap Medical.
For the acquisition, Fish Leap Medical said, is based on optimistic about the development of infectious disease prevention and control and infection control industry, and The Chinese medicine disinfection business in home care disinfection is very advantageous, whoed the holding of Chinese medicine is conducive to the optimal allocation of fish leap medical resources.
After the signing of the formal agreement between the two sides, Fish Leap Medical will take a 100% stake in China Excellent Medicine, and with the coordinated integration of the two sides in channels, resources, etc., will have a positive role in promoting the profitability, performance growth and industry status of Fish Leap Medical.merger and divestiture two-handed grasp
In 2014, Fish Leap Medical completed the acquisition of 100% of Shanghai Arms Group and China Resources Wandong 51.51% of the shares, and the Shanghai Arms Group into listed companies, divestiture of medical imaging business to China Resources Wandong, the integrated Fish Leap Medical will be household medical equipment and medical high-value supplies as the strategic direction of development.
in the home medical equipment, fish leap medical channel advantages are obvious, the variety layout is complete.
high-value consumables, Fish Leap Medical has grown in size after aggressive acquisitions over the past few years. The most important one was the acquisition of Suzhou Medical Supplies Factory in 2009 for 31 million yuan, and strategic foray into the field of medical supplies.
In 2016, Fish Leap Medical, at a premium of more than 400%, acquired a 61.6225 percent stake in Zhongyou Pharmaceuticals for 860 million yuan, with the provision of surgical instruments and disinfection services to hospitals as an entry point to expand the hospital's supply outsourcing business by intervening in hospital supply chain management.
In addition, the disinfection business of Chinese and excellent medicine can not only be effectively combined with the surgical equipment plate of the listed company subsidiary, Shanghai Machinery Group, to further enhance the competitiveness of the surgical equipment sector, but also with the help of the OTC strength of Fish Leap Medical, to open up the market and enrich its business in the good life sector.
in 2017, Fish Leap Medical has significantly accelerated its pace on the "buy-to-buy" path. According to incomplete statistics of The New Kangjie, in 2017 Fish Leap Medical acquired stakes in four enterprises and participated in the launch and subscription of two medical industry mergers and acquisitions funds.Acquisitions:
In February, Fish Leap Medical acquired defibrillator maker Metax through its German subsidiary Yuwell Germany GmbH, which brings down
the world-class brand Pomecon ®;
November,
, a wholly owned subsidiary of Fish Leap Medical, acquired a 100% stake in Yuke Orthopaedics for 5 million yuan, and in December, Wandong Medical, a subsidiary of Fish Leap Medical, announced that it would buy Yum Medical for 248 million euros
(about 1,937 million yuan).Mergers and Acquisitions Fund: in May,
, with its own capital of 20 million yuan, to participate in the subscription of HuagaiXin Health Investment Chengdu Partnership launched the medical industry fund
Among them, Fish Leap Medical contributed 100 million yuan, accounting for 12.5% of the fund's share. Investments include medicine and health and related big data, the Internet, new technologies, etc. (New Kangjie)